StocksIntra-Cellular Therapies IncITCI

ITCI

Intra-Cellular Therapies Inc

42.89 1.35 (3.25%)
Delayed Prices By NASDAQ, in USD Market Closed
Trade
S
42.83
B
42.97

Overview

Prev Close42.89
Day's Range40.47 - 42.92
52 Week Range22.92 - 44.69
Average Volume (3m)428.28K
1-Year Return66.33%
Beta1.0927
Market Cap3.49B
P/E Ratio
Revenue55.75M
EPS-3.0475
Dividend (Yield)0 (0%)
1 Day 1 Week 1 Month 3 Months 6 Months 1 Year 3 Years Max
Chart times in UTC
Industry Biotechnology
CEO Sharon Mates, PhD
Employees 383

FINANCIAL SUMMARY

For the fiscal year ended 31/12/2020: Intra-Cellular Therapies Inc's revenues increased by 37,537.11% and amounted to 22.81M. Net income decreased by 53.67% to -227.01M. Net assets increased by 236.84% to 656.86M and EPS decreased from -2.68 to -3.23.
ITCI's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
90.69%
Net Profit Margin
-63,937.24%
Operating Margin
-429.85%
Return On Investment
-40.69%
09/20
12/20
03/21
06/21
Total Revenue
7.37M
12.45M
15.88M
20.05M
Gross Profit
6.81M
11.31M
14.42M
18.01M
Operating Income
-55.94M
-61.33M
-53.22M
-69.14M
Net Income
-55.18M
-60.7M
-52.74M
-68.74M